Matthew A. Gubens
182 works · 21,359 citations · h-index 46
Top works
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
- Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
- Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
- Non–Small Cell Lung Cancer, Version 4.2024
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
- Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
- 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
- NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
- Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction
- Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
- Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.